INFLUENCE OF DURATION OF EXPOSURE TO 5-FLUOROURACIL ON ANTIPROLIFERATING ACTIVITY AGAINST CULTURED MURINE LYMPHOMACELLSKANZAWA F; HOSHI A; KURETANI K et al.1981; BR. J. CANCER; ISSN 0007-0920; GBR; DA. 1981; VOL. 44; NO 5; PP. 757-759; BIBL. 14 REF.Article

ISOLATION AND CHARACTERIZATION OF THE MURINE LYMPHOMA L5178Y CELL LINE HIGHLY RESISTANT TO 5-FLUOROURACILKANZAWA F; HOSHI A; KURETANI K et al.1980; J. PHARMACOBIO-DYN.; ISSN 0386-846X; JPN; DA. 1980; VOL. 3; NO 8; PP. 390-394; BIBL. 20 REF.Article

INFLUENCE OF ROUTE OF ADMINISTRATION OF ANTILEUKEMIC ACTIVITY OF CYCLOCYTIDINE = INFLUENCE DE LA VOIE D'ADMINISTRATION SUR L'ACTION ANTILEUCEMIQUE DE LA CYCLOCYTIDINEHOSHI A; KANZAWA F; KURETANI K et al.1972; GANN; JAP.; DA. 1972; VOL. 63; NO 2; PP. 279-280; BIBL. 3 REF.Serial Issue

MECHANISM OF CYTOTOXICITY OF 5-FLUOROURACIL: DISTINCTION BETWEEN THE IRREVERSIBLE CYTOTOXIC EFFECT OF 5-FLUOROURIDINE AND THE REVERSIBLE CYTOTOXIC EFFECT OF 5-FLUORO-2'-DEOXYURIDINE ON MURINE LYMPHOMA L5178Y CELLS IN CULTUREKANZAWA F; HOSHI A; KURETANI K et al.1980; Z. KREBSFORSCH. KLIN. ONKOL.; ISSN 0084-5353; DEU; DA. 1980; VOL. 98; NO 1; PP. 85-90; BIBL. 18 REF.Article

EFFECT OF CENTROPHENOXINE ON CYCLOPHOSPHAMIDE CONCENTRATION IN BLOOD.KANZAWA F; HOSHI A; KURETANI K et al.1976; GANN; JAP.; DA. 1976; VOL. 67; NO 4; PP. 595-599; BIBL. 9 REF.Article

EFFECT OF STRUCTURAL MODIFICATION ON ANTITUMOR ACTIVITY OF HALOACETYLPHENOTHIAZINES = EFFET DE MODIFICATION STRUCTURALE SUR L'ACTIVITE ANTITUMORALE DES HALOACETYLPHENOTHIAZINESKANZAWA F; HOSHI A; KURETANI K et al.1972; GANN; JAP.; DA. 1972; VOL. 63; NO 3; PP. 375-378; BIBL. 4REF.Serial Issue

DIFFERENCES BETWEEN 5-FLUORO-2'-DEOXYURIDINE AND 5-FLUOROURIDINE IN THEIR CYTOTOXIC EFFECT ON GROWTH OF MURINE LYMPHOMA L5178Y CELLS IN IN VIVO AND IN VITRO SYSTEMSKANZAWA F; HOSHI A; KURETANI K et al.1980; EUR. J. CANCER; ISSN 0014-2964; GBR; DA. 1980; VOL. 16; NO 8; PP. 1087-1092; BIBL. 21 REF.Article

ANTITUMOR ACTIVITY OF 1-ACYLOXYMETHYL DERIVATIVES OF 5-FLUOROURACIL AGAINST L1210 LEUKEMIAHOSHI A; INOMATA M; KANZAWA F et al.1982; J. PHARMACOBIO-DYN; ISSN 0386-846X; JPN; DA. 1982; VOL. 5; NO 3; PP. 208-212; BIBL. 6 REF.Article

MURINE LYMPHOMA L5178Y CELLS RESISTANT TO PURINE ANTAGONISTS: DIFFERENCES IN CROSS-RESISTANCE TO THIOGUANINE-PLATINUM (II) AND SELENOGUANINE-PLATINUM (II)KANZAWA F; MAEDA M; SASAKI T et al.1982; J. NATL. CANCER INST.; ISSN 0027-8874; USA; DA. 1982; VOL. 68; NO 2; PP. 287-291; BIBL. 25 REF.Article

PYRIMIDINE NUCLEOSIDES. VI. SYNTHESES AND ANTICANCER ACTIVITIES OF N⁴-SUBSTITUTED 2,2'-ANHYDRONUCLEOSIDESKANAI T; ICHINO M; HOSHI A et al.1974; J. MEDICIN. CHEM.; U.S.A.; DA. 1974; VOL. 17; NO 10; PP. 1076-1078; BIBL. 22 REF.Article

POTENTIATION OF ANTITUMOR ACTIVITY OF CYCLOPHOSPHAMIDE BY CENTROPHENOXINE = POTENTIALISATION DE L'ACTION ANTITUMORALE DU CYCLOPHOSPHAMIDE PAR LA CENTROPHENOXINEKANZAWA F; HOSHI A; TSUDA S et al.1972; GANN; JAP.; DA. 1972; VOL. 63; NO 4; PP. 409-413; BIBL. 6 REF.Serial Issue

ANTITUMOR ACTIVITY OF 3',5'-DIESTERS OF 5-FLUORO-2'-DEOXYURIDINE AGAINST MURINE LEUKEMIA L1210 CELLSKANZAWA F; HOSHI A; KURETANI K et al.1981; CANCER CHEMOTHER. PHARMACOL.; ISSN 0344-5704; DEU; DA. 1981; VOL. 6; NO 1; PP. 19-23; BIBL. 30 REF.Article

EFFECT AND TOXICITY OF COMBINATION TREATMENT INCLUDING CYCLOCYTIDINE OR CYTOSINE ARABINOSIDE IN "L1210 AND SARCOMA-180 SYSTEMSHOSHI A; KANZAWA F; IIGO M et al.1975; GANN; JAP.; DA. 1975; VOL. 66; NO 5; PP. 539-546; BIBL. 12 REF.Article

ANTITUMOR ACTIVITY OF PROTEIN MOIETY OF PSEUDOMONAS AERUGINOSA ENDOTOXIN = ACTION ANTITUMORALE DE LA FRACTION PROTEIQUE DE L'ENDOTOXINE DE P. A.HOSHI A; KANZAWA F; KURETANI K et al.1972; GANN; JAP.; DA. 1972; VOL. 63; NO 4; PP. 503-504; BIBL. 13 REF.Serial Issue

SPECIFIC INHIBITION OF DNA SYNTHESIS BY CYCLOCYTIDINEHOSHI A; YOSHIDA M; KANZAWA F et al.1972; CHEM. PHARM. BULL.; JAP.; DA. 1972; VOL. 20; NO 10; PP. 2286-2287; BIBL. 3REF.Serial Issue

Antitumor activities of a new indolocarbazole substance, NB-506, and establishment of NB-506-resistant cell lines, SBC-3/NBKANZAWA, F; NISHIO, K; KUBOTA, N et al.Cancer research (Baltimore). 1995, Vol 55, Num 13, pp 2806-2813, issn 0008-5472Article

In vitro interactions of a new derivative of spicamycin, KRN5500, and other anticancer drugs using a three-dimensional modelKANZAWA, F; NISHIO, K; FUKUOKA, K et al.Cancer chemotherapy and pharmacology. 1999, Vol 43, Num 5, pp 353-363, issn 0344-5704Article

Clonogenic cell assay for carcinoma of the lung = Test des cellules clonogènes pour la tumeur du poumonKANZAWA, F; HOSHI, A; SHIMIZU, E et al.Gann. 1984, Vol 75, Num 1, pp 81-88, issn 0016-450XArticle

Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatinFUKUDA, M; OHE, Y; KANZAWA, F et al.Anticancer research. 1995, Vol 15, Num 2, pp 393-398, issn 0250-7005Article

Characterization of an etoposide-resistant human small-cell lung cancer cell lineMINATO, K; KANZAWA, F; NISHIO, K et al.Cancer chemotherapy and pharmacology. 1990, Vol 26, Num 5, pp 313-317, issn 0344-5704, 5 p.Article

Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assayMATSUSHIMA, Y; KANZAWA, F; HOSHI, A et al.Cancer chemotherapy and pharmacology. 1985, Vol 14, Num 2, pp 104-107, issn 0344-5704Article

Combination effects of TAS-103, a novel dual topoisomerase I and II inhibitor, with other anticancer agents on human small cell lung cancer cellsSUNAMI, T; NISHIO, K; KANZAWA, F et al.Cancer chemotherapy and pharmacology. 1999, Vol 43, Num 5, pp 394-401, issn 0344-5704Article

Antitumor activity of alkylesters of 5-fluoro-2'-deoxyuridine 5'-monophosphate (FDUMP) against murine lymphoma L 5178Y resistant TO 5-fluoro-2'-deoxyuridineKANZAWA, F; MATSUSHIMA, Y; ISHIHARA, J.-I et al.Journal of pharmacobio-dynamics. 1986, Vol 9, Num 8, pp 688-693, issn 0386-846XArticle

Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell lineKUBOTA, N; KANZAWA, F; NISHIO, K et al.Biochemical and biophysical research communications (Print). 1992, Vol 188, Num 2, pp 571-577, issn 0006-291XArticle

Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer : characterization and mechanism of resistanceKANZAWA, F; SUGIMOTO, Y; MINATO, K et al.Cancer research (Baltimore). 1990, Vol 50, Num 18, pp 5919-5924, issn 0008-5472, 6 p.Article